CEP-14513
CEP-14513 is an ALK inhibitor with an IC50 of 4 nM. CEP-14513 also inhibits insulin receptor, VEGFR2, TIE2 and DLK kinases, but does not inhibit MET, IKKβ, or CDK1/2/5. CEP-14513 induces cancer cell apoptosis. CEP-14513 is applicable to research related to non-small cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, and diffuse large B-cell lymphoma.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 856693-04-4
- Formel: C34H36N6O3
- Molecular Weight:576.70
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle VEGFR Isoform-spezifische Produkte anzeigen
MoreAlle MAP3K Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
VEGFR2 |
Tie2 |
MAP3K12/DLK |
CEP-14513 inhibits the proliferation of ALK-mutant cell lines, with a cellular IC50 value of 10-30 nM[1].
CEP-14513 potently inhibits purified NPM-ALK fusion kinase with an IC50 < 5 nM, while it shows no inhibitory activity against CDK1/CDK2/CDK5, MET and IKKβ[2].
CEP-14513 inhibits tyrosine phosphorylation in NPM-ALK-transformed cells, with an IC50 < 30 nM[2].
CEP-14513 selectively inhibits proliferation and colony formation of NPM-ALK-transformed cells, and induces their apoptosis, while exhibits extremely low activity against ALK-negative K562 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 856693-04-4
-
Molecular Weight 576.70
-
Formel C34H36N6O3
-
SMILES
O=C(OC1=CC=C2C(=C1)C=3C(=C4C(C5=CN(N=C5CC4)C)=C6C(=O)NCC63)N2CC(C)C)NCC7=CC=C(C=C7)N(C)C
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1].
Puig de la Bellacasa R, et al. ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer Res. 2013 Apr;2(2):72-86.
[Content Brief]
[2]. Gunby RH, et al. Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy. Anticancer Agents Med Chem. 2007;7(6):594-611. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Powered by Bioz